Variant position: 382 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 1040 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human DIFQLLLDHPDRVLLTFDGF DEFKFRFTDRERHCSPTDPTS
Chimpanzee DIFQLLLDHPDRVLLTFDGF DEFKFRFTDRERHCSPTDPTS
Mouse DVFQFLLDHPDRVLLTFDGL DEFKFRFTDRERHCSPIDPTS
Bovine DVFQVLLDHPERILLTFDGF DEFRFRFTDQERHCCPTAPTS
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 1040 Nucleotide-binding oligomerization domain-containing protein 2
293 – 618 NACHT
225 – 1040 Missing. In isoform 3.
379 – 379 D -> A. No disruption in NOD2-CARD9 interaction.
Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome.
Kanazawa N.; Okafuji I.; Kambe N.; Nishikomori R.; Nakata-Hizume M.; Nagai S.; Fuji A.; Yuasa T.; Manki A.; Sakurai Y.; Nakajima M.; Kobayashi H.; Fujiwara I.; Tsutsumi H.; Utani A.; Nishigori C.; Heike T.; Nakahata T.; Miyachi Y.;
Cited for: VARIANTS EOS TRP-334; GLU-382; LEU-496; THR-513; PRO-605; THR-612 AND LYS-670; CHARACTERIZATION OF VARIANTS EOS GLU-382; LEU-496; THR-513; PRO-605 AND LYS-670;
Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis.
Okafuji I.; Nishikomori R.; Kanazawa N.; Kambe N.; Fujisawa A.; Yamazaki S.; Saito M.; Yoshioka T.; Kawai T.; Sakai H.; Tanizaki H.; Heike T.; Miyachi Y.; Nakahata T.;
Arthritis Rheum. 60:242-250(2009)
Cited for: VARIANT GLY-383; VARIANTS BLAUS GLN-334; TRP-334 AND TYR-495; VARIANTS EOS GLU-382; LEU-496; THR-513; PRO-605 AND LYS-670;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.